Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry

Ji, Hye Young; Lee, Hye Won; Kim, Young Hoon; Jeong, Dong Won

doi:10.1016/j.jchromb.2005.08.023

Cited by 66 publications

(38 citation statements)

References 22 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To investigate the PK model of MEL, measurement of the concentrations of MEL and its metabolites (5-HMEL and 5-CMEL) in biological samples is necessary. Several reports have examined the concentration of MEL in human and animal plasma [4][5][6][7][8][9] and the metabolism of MEL. 2,3) However, these studies did not concomitantly measure 5-HMEL and 5-CMEL.…”

Section: )mentioning

confidence: 99%

“…The majority of these methods employ HPLC-ultraviolet (HPLC-UV) [2][3][4][5][6] or HPLCfluorescence (HPLC-FL) 10) spectrophotometry. Other reports employed LC-MS, 2) liquid chromatography-tandem mass spectrometry (LC-MS/MS), [7][8][9] flow injection analysis-chemiluminescence (FIA-CL), 11) or electrochemical methods. 12) Simple and rapid sample preparation is an advantage of HPLC.…”

Section: )mentioning

confidence: 99%

See 1 more Smart Citation

The Measurement of Meloxicam and Meloxicam Metabolites in Rat Plasma Using a High-Performance Liquid Chromatography-Ultraviolet Spectrophotometry Method

Miyamoto

Aoyama

Matsumoto

2017

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

A high-performance liquid chromatography-ultraviolet spectrophotometry (HPLC-UV) method for the determination of meloxicam (MEL) and meloxicam metabolites (5′-hydroxy meloxicam (5-HMEL) and 5′-carboxy meloxicam (5-CMEL)) has been developed. After extraction of MEL, 5-HMEL, and 5-CMEL from rat plasma using Oasis HLB cartridges, the extracts were separated with a Luna C18 (2) 100 A column (5 µm, 4.6 150 mm, Phenomenex) using a mobile phase of 50 mM phosphate buffer (pH 2.15, solvent A) and acetonitrile (solvent B) at a flow rate of 0.8 mL/min in a linear gradient. The detection wavelength was 360 nm, and the internal standard (IS) was piroxicam. Each calibration curve was linear in the range of 40 to 1000 ng/mL (r 2 >0.999). The extraction rates of MEL, 5-HMEL, and 5-CMEL were greater than 86.9%. The intra-and inter-day accuracies were in the range of 95.0 to 119.0%, and the precision was 0.2 to 17.0%. To the best of our knowledge, this is the first report of the quantitative and qualitative measurement of meloxicam and each metabolite using an HPLC-UV method. Key words meloxicam; meloxicam metabolite; HPLC-UVThe aim of this study was to establish a procedure to study the pharmacokinetic (PK) model of meloxicam (MEL). MEL (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide) is a nonsteroidal anti-inflammatory drug (NSAID) that has selective inhibitory effects on the inducible isoform of cyclooxygenase-2. MEL is as effective as other NSAIDs in the treatment of rheumatoid arthritis and osteoarthritis in humans 1); it is used as an anti-inflammatory agent and analgesic in animals. 2)Generally, administrated meloxicam is first metabolized to a 5′-hydroxymethyl metabolite (5-HMEL) by CYP2C9 (major) and CYP3A4 (minor); it is then metabolized to a 5′-carboxy metabolite (5-CMEL). 3)Studies of the human plasma concentration/time profile of MEL after a single oral administration indicate that the graph exhibits bimodal peaks. 4,5) These reports suggest that MEL undergoes enterohepatic circulation. Taking these findings into account, we are planning to investigate the process by which MEL is metabolized to 5-HMEL and 5-CMEL (e.g., glucuronide conjugate, CYP metabolism). To investigate the PK model of MEL, measurement of the concentrations of MEL and its metabolites (5-HMEL and 5-CMEL) in biological samples is necessary. Several reports have examined the concentration of MEL in human and animal plasma [4][5][6][7][8][9] and the metabolism of MEL.2,3) However, these studies did not concomitantly measure 5-HMEL and 5-CMEL. The development of a system that enables the detection of MEL, 5-HMEL, and 5-CMEL is required.Various analytical methods for determining MEL in biological samples have been reported. The majority of these methods employ HPLC-ultraviolet (HPLC-UV) 2-6) or HPLCfluorescence (HPLC-FL) 10) spectrophotometry. Other reports employed LC-MS, 2) liquid chromatography-tandem mass spectrometry (LC-MS/MS), [7][8][9] flow injection analysis-chemiluminescence (FIA-CL), 11) or electroc...

show abstract

Section: )mentioning

confidence: 99%

Section: )mentioning

confidence: 99%

The Measurement of Meloxicam and Meloxicam Metabolites in Rat Plasma Using a High-Performance Liquid Chromatography-Ultraviolet Spectrophotometry Method

Miyamoto

Aoyama

Matsumoto

2017

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

show abstract

“…For measurement of meloxicam concentrations in plasma samples, 250 μL of plasma was mixed with 20 μL of the internal standard plus 200 μL of acetonitrile acidified with H 3 PO 4 0.1% (v/v), and treated in the same way for calibration samples mentioned above (Velpandian et al, 2000;Ji et al, 2005).…”

Section: Calibration and Sample Preparationmentioning

confidence: 99%

“…AUMC was obtained by plotting mean meloxicam plasma concentration multiplied by time versus time. MRT was calculated by dividing AUMC over AUC 0-24 (Velpandian et al, 2000) and (Ji et al, 2005).…”

Section: Pharmacokinetic (Pk) Evaluationmentioning

confidence: 99%

In vitro and In vivo Evaluation of Tablets Containing Meloxicam- PEG 6000 Ball-Milled Co-Ground Mixture

Etman¹,

Shekedef²,

Nada³

et al. 2017

J App Pharma Sci

View full text Add to dashboard Cite

This study aimed at a) preparing meloxicam (MLX) tablets containing ball-milled co-ground mixture with PEG 6000 (1:4); b) evaluating the relevant in vitro quality parameters and stability; and c) comparing the bioavailability of the developed tablets with that of a reference meloxicam tablet (Mbc  ) in 6 human subjects. The dissolution rate of the prepared tablets was higher than that containing ball-milled or un-milled drug alone, as well as higher than four marketed meloxicam tablets. Upon storage for 12 months at 25±1ºC / 60% RH, no remarkable changes in physical appearance of the prepared tablets, % drug content, thickness, disintegration time and in dissolution rate were observed. The prepared meloxicam tablets showed higher bioavailability which was indicated by significant higher AUC and significant shorter Tmax. The bioavailability of the developed test tablets was 126.45%, relative to the marketed brand product (Mbc  tablets). Grinding of MXL with PEG 6000 resulted in a fast MLX release, which may provide rapid onset of action and allow also a reduction of required dose necessary to obtain the therapeutic effect. This, in turn, may further reduce the most common side effects observed with non-steroidal anti-inflammatory drugs (NSAIDs).

show abstract

“…Therefore, it is important to design enhancement techniques to assist the dermal delivery of IBU, and several research has been done to develop the topical and transdermal IBU formulations 7 9 . These systems have been employed to improve the delivery of IBU through the skin, and it have been developed the different dermal formulations such as patches 7 , gels 8 and liposomes 9 incorporating various permeation enhancers. In addition, strategies using nanoparticles and nanocarriers have also been demonstrated 9 .…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic Studies of Gel System Containing Ibuprofen Solid Nanoparticles

2016

View full text Add to dashboard Cite

Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry

Cited by 66 publications

References 22 publications

The Measurement of Meloxicam and Meloxicam Metabolites in Rat Plasma Using a High-Performance Liquid Chromatography-Ultraviolet Spectrophotometry Method

The Measurement of Meloxicam and Meloxicam Metabolites in Rat Plasma Using a High-Performance Liquid Chromatography-Ultraviolet Spectrophotometry Method

In vitro and In vivo Evaluation of Tablets Containing Meloxicam- PEG 6000 Ball-Milled Co-Ground Mixture

Pharmacokinetic Studies of Gel System Containing Ibuprofen Solid Nanoparticles

Contact Info

Product

Resources

About